Phase III Randomized Evidence for Bcma-Directed CAR T-Cell Therapy Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis (IMS 2026) - Sep 11, 2026 - Abstract #PA-352; Pres time: Sep 25, 2026; " Two phase III randomized trials met eligibility criteria: KarMMa-3 evaluating idecabtagene vicleucel versus investigator's-choice standard regimens and CARTITUDE-4 evaluating ciltacabtagene autoleucel versus pomalidomide-based standard regimens, comprising 805 randomized patients overall. Published phase III randomized evidence demonstrates a substantial progression-free survival benefit for BCMA-directed CAR-T therapy compared with standard regimens in RRMM. These findings support earlier integration of BCMA-directed CAR-T therapy in appropriately selected patients with relapsed/refractory disease."
CAR T-Cell Therapy • P3 data • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma
|
|
Vasu Malhotra1; Shreya G. Patel1; Kenneth Shain2
|